North America will account for 35% of the global interstitial cystitis (IC) drugs market

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report

Company Profiles

The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:

• Amneal Pharmaceuticals Inc: The company offers interstitial cystitis and other related drugs such as Pyridium.
• Astellas Pharma Inc: The company offers interstitial cystitis drugs such as Rosiptor.
• Bayer AG: The company offers interstitial cystitis drugs such as Aleve and Aktion.
• Eli Lilly and Co: The company offers interstitial cystitis and other related drugs such as Tadalafil.
• Johnson and Johnson: The company offers interstitial cystitis drugs such as Elmiron.
• Kyorin Pharmaceutical Co. Ltd.
• Mission Pharmacal Co.
• Perrigo Co. Plc
• Pfizer Inc.
• Purdue Pharma LP
• Seikagaku Corp.
• To gain access to more vendor profiles available with Technavio, buy the report!

Market Dynamics

The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

• By type, the market is segmented into oral therapy and intravesical therapy. The oral therapy segment accounted for the largest share of the market.
• By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market.

Related Reports:

Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.

Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this interstitial cystitis (IC) drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of interstitial cystitis (IC) drugs market between 2023 and 2027
• Precise estimation of the size of interstitial cystitis (IC) drugs market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of interstitial cystitis (IC) drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of interstitial cystitis (IC) drugs market vendors

Browse for Technavio "Health Care" Research Reports

Table of Content

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem
• • Exhibit 01: Parent market
  • Exhibit 02: Market characteristics

• 2.2 Value chain analysis
• • Exhibit 03: Value chain analysis: Pharmaceuticals

3 Market Sizing

• 3.1 Market definition
• • Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• • Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025 
• • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
  • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• • Exhibit 08: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers 
• • Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers 
• • Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants 
• • Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes 
• • Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry
• • Exhibit 13: Threat of rivalry

• 4.7 Market condition
• • Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Type

• 5.1 Market segments
• • Exhibit 15: Type - Market share 2020-2025 (%)

• 5.2 Comparison by Type
• • Exhibit 16: Comparison by Type

• 5.3 Oral therapy - Market size and forecast 2020-2025 
• • Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million)
  • Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%)

• 5.4 Intravesical therapy - Market size and forecast 2020-2025 
• • Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million)
  • Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%)

• 5.5 Market opportunity by Type 
• • Exhibit 21: Market opportunity by Type

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation 
• • Exhibit 23: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison 
• • Exhibit 24: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025 
• • Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
  • Exhibit 26: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025 
• • Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
  • Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025 
• • Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)
  • Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025 
• • Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
  • Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries 
• • Exhibit 33: Key leading countries

• 7.8 Market opportunity by geography 
• • Exhibit 34: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges
• • Exhibit 35: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• • Exhibit 36: Vendor landscape

• 9.3 Landscape disruption
• • Exhibit 37: Landscape disruption
  • Exhibit 38: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered
• • Exhibit 39: Vendors covered

• 10.2 Market positioning of vendors 
• • Exhibit 40: Market positioning of vendors

• 10.3 Astellas Pharma Inc.
• • Exhibit 41: Astellas Pharma Inc. - Overview
  • Exhibit 42: Astellas Pharma Inc. - Product and service
  • Exhibit 43: Astellas Pharma Inc. - Key news
  • Exhibit 44: Astellas Pharma Inc. - Key offerings

• 10.4 Bayer AG
• • Exhibit 45: Bayer AG - Overview
  • Exhibit 46: Bayer AG - Business segments
  • Exhibit 47: Bayer AG - Key news
  • Exhibit 48: Bayer AG - Key offerings
  • Exhibit 49: Bayer AG - Segment focus

• 10.5 Johnson and Johnson Inc. 
• • Exhibit 50: Johnson and Johnson Inc. - Overview
  • Exhibit 51: Johnson and Johnson Inc. - Business segments
  • Exhibit 52: Johnson and Johnson Inc. - Key news
  • Exhibit 53: Johnson and Johnson Inc. - Key offerings
  • Exhibit 54: Johnson and Johnson Inc. - Segment focus

• 10.6 Novartis AG
• • Exhibit 55: Novartis AG - Overview
  • Exhibit 56: Novartis AG - Business segments
  • Exhibit 57: Novartis AG - Key news
  • Exhibit 58: Novartis AG - Key offerings
  • Exhibit 59: Novartis AG - Segment focus

• 10.7 Perrigo Co. Plc
• • Exhibit 60: Perrigo Co. Plc - Overview
  • Exhibit 61: Perrigo Co. Plc - Business segments
  • Exhibit 62: Perrigo Co. Plc - Key news
  • Exhibit 63: Perrigo Co. Plc - Key offerings
  • Exhibit 64: Perrigo Co. Plc - Segment focus

• 10.8 Pfizer Inc.

• 10.9 Seikagaku Corp.
• • Exhibit 69: Seikagaku Corp. - Overview
  • Exhibit 70: Seikagaku Corp. - Business segments
  • Exhibit 71: Seikagaku Corp. - Key offerings
  • Exhibit 72: Seikagaku Corp. - Segment focus

• 10.10 Sun Pharmaceutical Industries Ltd. 
• • Exhibit 73: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service
  • Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news
  • Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings

• 10.11 Teva Pharmaceutical Industries Ltd. 
• • Exhibit 77: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 Viatris Inc.
• • Exhibit 81: Viatris Inc. - Overview
  • Exhibit 82: Viatris Inc. - Business segments
  • Exhibit 83: Viatris Inc. - Key offerings
  • Exhibit 84: Viatris Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$ 
• • Exhibit 85: Currency conversion rates for US$

• 11.3 Research methodology
• • Exhibit 86: Research Methodology
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Information sources

• 11.4 List of abbreviations 
• • Exhibit 89: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/interstitial-cystitis-ic-drugs-market-size-to-increase-by-usd-369-58-million-analysis-of-major-players-as-well-as-the-key-contributor-region---technavio-301732385.html

SOURCE Technavio